By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agilis Biotherapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Agilis Biotherapeutics And National Taiwan University Enter Into Worldwide, Exclusive License Agreement For The Gene Therapy Treatment Of AADC Deficiency 1/28/2016 9:42:41 AM
Agilis Biotherapeutics Names Former H. Lundbeck A/S (LUN.CO) Executive, Christopher J. Silber, MD, As Chief Medical Officer 1/25/2016 7:32:12 AM
Agilis Biotherapeutics Named As Top Company To Watch 11/19/2015 11:46:57 AM
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For AGIL-AS For The Treatment Of Angelman Syndrome 11/4/2015 9:12:38 AM
Agilis Biotherapeutics And University of South Florida Enter Into Worldwide, Exclusive License Agreement For The Treatment Of Cognitive Disorders Using Reelin-Based Therapies 9/17/2015 10:47:29 AM
Agilis Biotherapeutics Appoints Arthur Tzianabos, Ph.D., To The Board Of Directors 9/10/2015 11:23:29 AM
Agilis Biotherapeutics And The University of South Florida Enter Into Worldwide, Exclusive License Agreement For Angelman Syndrome Gene Therapy 5/13/2015 11:18:11 AM
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson As Chief Scientific Officer 11/24/2014 9:15:34 AM
Agilis Biotherapeutics Announces Appointment Of Dr. Paola Leone To Scientific Advisory Board 10/7/2014 10:12:05 AM
Agilis Biotherapeutics Appoints Dr. James E. Darnell, Jr. Of Rockefeller University To Scientific Advisory Board 9/30/2014 9:57:52 AM
12
//-->